NDA 220787 · Wockhardt Bio AG
Zaynich
Cefepime Hydrochloride, Zidebactam · Intravenous
NovelPriority reviewCDER novel approval, May 29, 2026: To treat complicated urinary tract infections, including pyelonephritis, caused by designated susceptible microorganisms
Last checked: Nov 19, 2026Latest source record: May 29, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2026
May 29, 2026
Approved uses
1
Original approval plus efficacy supplements
Registered trials
78
22 Phase 3, 8 recruiting
FAERS reports
1
1 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Oct 16, 2026.
ZAYNICH is a combination of cefepime, a cephalosporin antibacterial, and zidebactam, a beta-lactamase inhibitor and non-beta-lactam antibacterial indicated for the treatment of adult patients with complicated urinary tract infections (cUTI) including pyelonephritis caused by designated susceptible microorganisms. ( 1.1 ) Usage to Reduce Development of Drug-Resistant Bacteria To reduce the development of drug-resistant bacteria and maintain the effectiveness of ZAYNICH and other antibacterial drugs, ZAYNICH should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. ( 1.2 ) 1.1 Complicated Urinary Tract Infections, including Pyelonephritis ZAYNICH is indicated for the treatment of adult patients with complicated urinary tract infections (cUTI) including pyelonephritis caused by the following susceptible microorganisms: Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Enterobacter cloacae complex, and Pseudomonas aeruginosa . 1.2 Usage to Reduce Development of Drug-Resistant Bacteria To reduce the development of drug-resistant bacteria and maintain the effectiveness of ZAYNICH and other antibacterial drugs, ZAYNICH should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.
Mechanism: Cefepime and zidebactam, components of ZAYNICH, are antibacterial drugs [see Microbiology ( 12.4 )] .
Therapeutic areas: Infectious disease and vaccines · Kidney and urology
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- May 29, 2026 Original approval · Type 1 - New Molecular Entity and Type 4 - New Combination · priority review NovelLabelLetterReview
1 products under this application
- ZAYNICH · CEFEPIME HYDROCHLORIDE EQ 2GM BASE/VIAL; ZIDEBACTAM 1GM/VIAL · POWDER, INTRAVENOUS · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Cefepime" as an intervention, any sponsor and status, largest first.
- Effect of Antibiotic Choice On ReNal Outcomes (ACORN)Pivotal-lookingCompleted
Vanderbilt University Medical CenterAcademic, hospital or other
NCT05094154 · 2,634 participants · Start Nov 10, 2021 · Primary completion Oct 21, 2022
Drug: anti-pseudomonal cephalosporin; anti-pseudomonal penicillin · For: Sepsis; AKI; Neurotoxicity
Sites: Nashville, Tennessee
- Safety and Efficacy Study of Cefepime-AAI101 in the Treatment of Complicated Urinary Tract InfectionsPivotal-lookingCompleted
AllecraIndustry
NCT03687255 · 1,043 participants · Start Sep 24, 2018 · Primary completion Jan 30, 2020
Drug: cefepime/AAI101 combination; Piperacillin/tazobactam · For: Urinary Tract Infections
Sites: Anaheim, California; Buena Park, California; Tampa, Florida · 24 sites in all
- Gram-Negative Bloodstream Infection Oral Antibiotic Therapy TrialPivotal-lookingRecruiting
Johns Hopkins UniversityAcademic, hospital or other
NCT06080698 · 1,030 participants (planned) · Start Feb 22, 2024 · Primary completion May 31, 2027
Drug: Intravenous Antibiotics; Oral Antibiotics · For: Gram-negative Bacteremia
Sites: San Francisco, California; Denver, Colorado; Baltimore, Maryland · 11 sites in all
- Study of Cefepime-tazobactam (FEP-TAZ) in Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP)Pivotal-lookingStatus unknown
WockhardtIndustry
NCT03630081 · 1,004 participants (planned) · Start Jan 2024 · Primary completion Jan 2026
Drug: WCK 4282 (FEP-TAZ) 4 g; Meropenem and 1 more · For: Complicated Urinary Tract Infection; Acute Pyelonephritis
- Safety and Efficacy Study of Ftortiazinon in the Treatment of Patients With Complicated Urinary Tract Infections Caused by P. AeruginosaPivotal-lookingCompleted
Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian FederationAcademic, hospital or other
NCT03638830 · 777 participants · Start Oct 17, 2018 · Primary completion Nov 23, 2022
Drug: Ftortiazinon (tablets 300 mg) 1/2 dose +placebo+ Maxipim; Ftortiazinon (tablets 300 mg) full dose + Maxipim · For: Patients With Complicated Urinary Tract Infections Caused by P. Aeruginosa; Pseudomonas Aeruginosa; Pseudomonas Infections and 1 more
Sites: Saint Petersburg, Russia; Vsevolozhsk, Russia · 5 sites in all
- A Pragmatic Clinical Trial Comparing the Risk of Acute Kidney Injury During Treatment With Vancomycin and Piperacillin-Tazobactam vs. Vancomycin and Cefepime in Hospitalized PatientsPivotal-lookingRecruiting
University of PennsylvaniaAcademic, hospital or other
NCT06954129 · 750 participants (planned) · Start Jan 28, 2026 · Primary completion May 2029
Drug: Vancomycin; Piperacillin-tazobactam and 1 more · For: Acute Kidney Injury
Sites: Philadelphia, Pennsylvania
- Safety and Efficacy Study of Cefepime/VNRX-5133 in Patients With Complicated Urinary Tract InfectionsPivotal-lookingCompleted
Venatorx Pharmaceuticals, Inc.Industry
NCT03840148 · 661 participants · Start Aug 7, 2019 · Primary completion Dec 14, 2021
Drug: Cefepime/VNRX-5133 (taniborbactam); Meropenem · For: Urinary Tract Infections; Acute Pyelonephritis
Sites: Buena Park, California; Chula Vista, California; La Mesa, California · 78 sites in all
- Efficacy and Safety of Cefepime/Nacubactam or Aztreonam/Nacubactam Compared to Imipenem/Cilastatin in Subjects With Complicated Urinary Tract Infections or Acute Uncomplicated PyelonephritisPivotal-lookingCompleted
Meiji Seika Pharma Co., Ltd.Industry
NCT05887908 · 614 participants · Start May 23, 2023 · Primary completion Nov 22, 2024
Drug: co-administration of cefepime and nacubactam; co-administration of aztreonam and nacubactam and 1 more · For: Complicated Urinary Tract Infection; Acute Pyelonephritis; cUTI and 1 more
Sites: Pleven, Bulgaria; Rousse, Bulgaria; Silistra, Bulgaria · 61 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- acute kidney injury1
- encephalopathy1
- liver function test increased1
- off label use1
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2026 | 1 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Cefepime-induced neurotoxicity: a systematic review.
Payne LE, Gagnon DJ, Riker RR, et al. · Crit Care 2017 · Systematic Review
- Cefepime-induced neurotoxicity: systematic review.
Maan G, Keitoku K, Kimura N, et al. · J Antimicrob Chemother 2022 · Systematic Review
- Drug-Induced Myoclonus: A Systematic Review.
Rissardo JP, Fornari Caprara AL, Bhal N, et al. · Medicina (Kaunas) 2025 · Systematic Review
- Cefepime-Taniborbactam in Complicated Urinary Tract Infection.
Wagenlehner FM, Gasink LB, McGovern PC, et al. · N Engl J Med 2024 · Clinical Trial, Phase III, Comparative Study
- Effect of Cefepime/Enmetazobactam vs Piperacillin/Tazobactam on Clinical Cure and Microbiological Eradication in Patients With Complicated Urinary Tract Infection or Acute Pyelonephritis: A Randomized Clinical Trial.
Kaye KS, Belley A, Barth P, et al. · JAMA 2022 · Clinical Trial, Phase III, Comparative Study
- Cefepime and Mortality: A Systematic Review and Bayesian Meta-Analysis.
Sohani ZN, Zhong YJ, Afshar A, et al. · JAMA Netw Open 2026 · Systematic Review, Meta-Analysis
Sponsor: Wockhardt Bio AG
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.